

SUMMARY OF INFLUENZA H1N1 VACCINE PROCUREMENT IN LATIN AMERICA AND THE CARIBBEAN



Country	Total population (2008) ¹	10% of population	Source of vaccine	Number of doses purchased/donated	Vaccine Producer	Period of vaccination (estimated date of vaccine arrival)
Anguilla	14,000	1,400	RF	1,200	Sanofi (non-adjuvanted)	1-Feb
Antigua & Barbuda	85,000	8,500	RF	8,500	Sanofi (non-adjuvanted)	25-Jan
Argentina	39,883,000	3,988,300	RF	Canceled order	NA	
Aruba	105,000	10,500	Dutch gov't?			
Bahamas	338,000	33,800	RF	30,000	Sanofi (non-adjuvanted)	19-Jan
Barbados	255,000	25,500	RF	20,000	Sanofi (non-adjuvanted)	15-Jan
Belize	301,000	30,100	RF	8,000	Sanofi (non-adjuvanted)	2-Feb
Bermuda	67,000	6,700	RF	1,000	Sanofi (non-adjuvanted)	18-Jan
Bolivia	9,694,000	969,400	WHO Donation and RF	(900,000 in donation, 400,000 from RF ³) Total: 1,300,000	GSK (with adjuvant) from donation; Sanofi (non-adjuvanted) from RF	pending dates from WHO
Brazil	191,972,000	19,197,200	RF and direct purchase	9,999,880 (RF only)	Novartis (non-adjuvanted)-8,000,000 doses; Novartis (with adjuvant)-1,999,880 doses	March
British Virgin Islands	24,000	2,400	RF	2,000	Sanofi (non-adjuvanted)	1-Feb
Cayman Islands	48,000	4,800	RF	10,000	Sanofi (non-adjuvanted)	18-Jan
Chile	16,804,000	1,680,400	RF	602,660 doses (1,400,000 doses pending country approval) Total: 2,002,660	Sanofi (non-adjuvanted)	
Colombia	45,012,000	4,501,200	RF	1,999,930	Novartis (non-adjuvanted)--1,400,000 doses; Novartis (with adjuvant)- 599,930 doses	Feb. and Mar.
Costa Rica	4,519,000	451,900	RF	199,300 (1,600,000 doses pending country approval) Total: 1,799,300	Sanofi (non-adjuvanted)-199,300 doses	21-Jan
Cuba	11,205,000	1,120,500	WHO Donation	1,124,000	GSK (with adjuvant)	pending dates from WHO
Dominica	73,000	7,300		Country will not purchase vaccine		

SUMMARY OF INFLUENZA H1N1 VACCINE PROCUREMENT IN LATIN AMERICA AND THE CARIBBEAN



Country	Total population (2008) ¹	10% of population	Source of vaccine	Number of doses purchased/donated	Vaccine Producer	Period of vaccination (estimated date of vaccine arrival)
Dominican Rep.	9,953,000	995,300		Country will not purchase vaccine		
Ecuador	13,481,000	1,348,100	RF	1,200,000 doses available for purchase	Novartis (non-adjuvanted)- 754,000 doses; Novartis (with adjuvant)- 445,060 doses	
El Salvador	6,134,000	613,400	WHO Donation	675,000	GSK (with adjuvant)	pending dates from WHO
Grenada	104,000	10,400	RF	4,000	Sanofi (non-adjuvanted)	1-Feb
Guatemala	13,686,000	1,368,600	WHO Donation	1,300,000	Sanofi (non-adjuvanted)	pending dates from WHO
Guyana	763,000	76,300	WHO Donation	75,000	Sanofi (non-adjuvanted)	pending dates from WHO
Haiti	9,876,000	987,600	WHO Donation	1,000,000	Sanofi (non-adjuvanted)	pending dates from WHO
Honduras	7,319,000	731,900	WHO Donation and RF	(700,000 in donation, 515,000 from RF) Total: 1,215,000	Novartis (with adjuvant) from donation; Sanofi (non-adjuvanted) from RF	Jan 15 and Feb 22 (RF), pending dates from WHO
Jamaica	2,708,000	270,800	RF	25,000 (awaiting country confirmation to RF)	Sanofi (non-adjuvanted)	
Mexico	108,555,000	10,855,500	Direct purchase	30,000,000		
Montserrat	5,000	500	RF	1,500	Sanofi (non-adjuvanted)	28-Jan
Netherlands Antilles	195,000	19,500	Dutch gov't?			
Nicaragua	5,667,000	566,700	WHO Donation	550,000	Novartis (with adjuvant)	pending dates from WHO
Panama	3,399,000	339,900	RF	300,000	Sanofi (non-adjuvanted)	Dec 30 and Feb 22
Paraguay	6,238,000	623,800	WHO Donation	600,000	Sanofi (non-adjuvanted)	pending dates from WHO
Peru	28,837,000	2,883,700	RF	3,071,500 (1,920,210 doses ³)	595,510 doses Novartis (with adjuvant); 2,475,990 doses Novartis (non-adjuvanted)	22-Feb
St. Kitts y Nevis	40,000	4,000	RF	Vaccine available through RF, awaiting country response	Sanofi (non-adjuvanted)	

SUMMARY OF INFLUENZA H1N1 VACCINE PROCUREMENT IN LATIN AMERICA AND THE CARIBBEAN



Country	Total population (2008) ¹	10% of population	Source of vaccine	Number of doses purchased/donated	Vaccine Producer	Period of vaccination (estimated date of vaccine arrival)
St Lucia	170,000	17,000	RF	6,000	Sanofi (non-adjuvanted)	2-Feb
St Vincent and the Grenadines	109,000	10,900	RF	Vaccine available through RF, awaiting country response	Sanofi (non-adjuvanted)	
Suriname	515,000	51,500	WHO Donation and purchase from Dutch gov't	100,000	GSK (with adjuvant)	pending dates from WHO
Trinidad and Tobago	1,333,000	133,300	RF	80,000	Sanofi (non-adjuvanted)	18-Jan
Turks and Caicos	22,000	2,200	RF	7,600	Sanofi (non-adjuvanted)	18-Jan
Uruguay	3,349,000	334,900	RF	1,000,000 doses available for purchase but pending country approval	369,240 doses Novartis (non-adjuvanted); 630,700 doses Novartis (with adjuvant)	
Venezuela	28,121,000	2,812,100	RF	3,000,000 ³	Sanofi (non-adjuvanted)	
TOTAL						

1. Population estimates were taken from the UN population estimate 2008

2. Identified at risk populations taken from national plans of action (final versions or drafts). Some countries incorporated vaccinating large percentages of their entire populations into this estimate, therefore sub totals for WHO priority groups (HCWers, pregnant women and pop w/chronic diseases) are given, when available, as well a 10% population estimate for reference.

3. Pending payment to the RF

Last updated: 22 February 2010